POSTER: CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS)

Elias Jabbour,Fei Huang,Michael J Zoratti,Megan Rutherford,Hoora Moradian,Mehul Dalal,Ajibade Ashaye,Lucio N Gordan

doi:10.1016/s2152-2650(23)00549-9

POSTER: CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS)

Elias Jabbour, Fei Huang + Show 6 more

Open Access

https://doi.org/10.1016/s2152-2650(23)00549-9

Copy DOI

Journal: Clinical Lymphoma Myeloma and Leukemia

Publication Date: Aug 31, 2023

Affiliation: The University of Texas MD Anderson Cancer Center

#Number Needed To Treat #Chronic Phase Chronic Myeloid Leukemia + Show 4 more

Abstract
Full-Text PDF
Similar Papers

Abstract

POSTER: CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Clinical Lymphoma Myeloma and Leukemia

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.